Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Eisai Ltd ADR
(OP:
ESALY
)
N/A
UNCHANGED
Last Price
Updated: 3:59 PM EST, Jan 30, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Eisai Ltd ADR
< Previous
1
2
3
4
5
6
7
Next >
US Stock Futures Down Ahead Of Fed Speakers, Economic Data
September 28, 2022
Pre-open movers U.S. stock futures traded lower in early pre-market trade on Wednesday after closing mostly lower on Tuesday. The S&P 500 index dropped deeper into a bear market after hitting a fresh...
Via
Benzinga
Alzheimer's Progression Slowed Down By Biogen's New Drug In Late-Stage Study: Analyst Sees 25% Upside For Stock
September 28, 2022
Biogen, Inc. (NASDAQ: BIIB) and Eisai Co. Ltd. (OTC: ESALY) announced late Tuesday positive results from a late-stage study of their Alzheimer’s treatment candidate.
Via
Benzinga
Merck's Keytruda Combo Trial Fails To Meet Primary Goal In Liver Cancer
September 12, 2022
Via
Benzinga
Citi Is Bullish On This Large Pharma Stock On Upcoming Data Readout From Diabetes Candidate
August 25, 2022
Citi has increased peak risk-adjusted Eli Lilly And Co's (NYSE: LLY) tirzepatide forecasts (diabetes/ obesity/NASH) to more than $25 billion (previously $15 billion, consensus of around $16 billion).
Via
Benzinga
Biotech Daily: Merck's Two Combo Cancer Trials Miss Main Goal, Approval For Sinovac's COVID-19 Shot For Youngest Kids, Alnylam Aces Protein Disorder Trial
August 03, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Merck's Two Keytruda Combo Cancer Trials Miss Primary Goal
August 03, 2022
Via
Benzinga
The Daily Biotech Pulse: FDA Decision On Biogen Alzheimer's Drug Due In January, FDA Reviews Roche's Lymphoma Candidate, Rare Pediatric Tag For Kazia's Pediatric Brain Cancer Candidate
July 06, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Biogen Pops After Eisai Asks FDA To Approve A New Alzheimer's Treatment
May 10, 2022
Eisai finished submitting its application for lecanemab, another anti-amyloid drug.
Via
Investor's Business Daily
The Daily Biotech Pulse: Pfizer Acquires Migraine Drugmaker For $11B, Biogen Files For Second Alzheimer's Drug Approval, Longeveron CEO Leaves
May 10, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Biogen, Eisai Amend Their Alzheimer's Drug Marketing Pact
March 15, 2022
Via
Benzinga
Eisai - Biogen Seek Accelerated Approval For Their Second Alzheimer's Drug
May 10, 2022
Via
Benzinga
The Daily Biotech Pulse: SELLA In-licenses Oncology Asset, Merck's Pneumococcal Vaccine Review Extended, Arc Biopharma COVID Drug Flunks Mid-Stage Study
April 01, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours.
Via
Benzinga
Biogen, Eisai Unveil New Data On Another Alzheimer's Candidate, Lecanemab
March 22, 2022
In the partnership that spawned aducanumab, Eisai Co Ltd (OTC: ESALY) and Biogen Inc (NASDAQ: BIIB) have
Via
Benzinga
FDA Approves Second Indication For Merck's Keytruda In Endometrial Cancer
March 22, 2022
The
Via
Benzinga
News-Filled Day
March 15, 2022
The price of oil fell to below $100/oz on the prospect of lower demand from the PRC.
Via
Talk Markets
The Daily Biotech Pulse: Biogen, Eisai Amend Aduhelm Agreement; Anaptys Acne Drug Flunks Midstage Study; Merck, AstraZeneca Discontinue Prostate Cancer Trial
March 15, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours:
Via
Benzinga
Hopes For A Peace Accord
March 14, 2022
The winner today was BioNTech up 14.89% on hopes for new sales for the Covid-19 variant.
Via
Talk Markets
The Daily Biotech Pulse: Ocugen Faces Regulatory Setback, vTv CEO Quits, Biogen-Eisai Make Headway With Second Alzheimer's Antibody Treatment In Japan
March 04, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Merck's Keytruda Evaluated In Combination With Microbiome Therapeutic In...
Via
Benzinga
The Ruble Is Rubble
March 03, 2022
MSCI says Russian companies are
Via
Talk Markets
Merck-Eisai's Keytruda/Lenvima Combo Scores Japanese Approval For Kidney Cancer Setting
February 25, 2022
The Japanese Ministry of Health, Labour, and Welfare (MHLW) has approved Merck & Co Inc's (NYSE: MRK) Keytruda/Lenvima combo therapy for radically...
Via
Benzinga
Dampening Exuberance
February 09, 2022
The bond sell-off halted today but the Fed's plans mean this will resume.
Via
Talk Markets
Weakened Tech Stocks
February 03, 2022
There was a 0.5% rise in UK interest rates, twice what had been anticipated and moreover early, because of inflation risks.
Via
Talk Markets
The Daily Biotech Pulse: Novavax COVID Shot Authorized In Australia, Zymeworks Restructures, Orphan Drug Designation For Marker's Pancreatic Cancer Drug
January 20, 2022
Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Eisai Announces Publication Of Positive Data On Lenvima-Keytruda Combo In...
Via
Benzinga
CMS Proposes Coverage Of Biogen's Alzheimer's Drug, With Conditions Apply
January 12, 2022
The Centers for Medicare & Medicaid Services (CMS) released a proposed national coverage determination for Medicare to cover drugs that target amyloid for mild...
Via
Benzinga
Christmas is Coming
December 23, 2021
November saw a very modest increase in consumer spending, 0.6%. That means we are probably making up for it this month.
Via
Talk Markets
A Bit Of Good News
December 22, 2021
US growth figures for Q3 were up from forecasts of 2.1% at 2.3% but well down from the prior quarter level of 6.7%.
Via
Talk Markets
Biogen Outlines Aduhelm's Confirmatory Trial Plans, Data Expected In 2026
December 16, 2021
Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) are looking to get initial data from the FDA-mandated confirmatory trial for its Alzheimer’s...
Via
Benzinga
Uncertain Times
December 15, 2021
The UK inflation rate last month was 5.1%, not a good omen.
Via
Talk Markets
Europe Approves Merck-Eisai's Keytruda/Lenvima Combo Therapy For Endometrial Carcinoma
November 29, 2021
The European Commission has approved a combination of Merck & Co Inc's (NYSE: MRK) Keytruda plus Eisai Co Ltd's (OTC: ESALY) Lenvima for...
Via
Benzinga
Why Are Biogen Shares Gaining Today?
November 12, 2021
Biogen Inc (NASDAQ: BIIB) and Eisai Co Ltd (OTC: ESALY) have new data released for Aduhelm (aducanumab-avwa) in Alzheimer's disease. Related:...
Via
Benzinga
< Previous
1
2
3
4
5
6
7
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.